NA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America breast cancer diagnostics market is projected to register a CAGR of 9.5% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

North America Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the North America breast cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare GmbH

General Electric

Koninklijke Philips N.V.

FUJIFILM Corporation

Abbott

Hologic, Inc.

1 INTRODUCTION 48

1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

8.1 DRIVERS 78
- 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
- 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
- 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
- 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
- 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
- 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
- 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
- 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
- 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
- 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
- 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

9.1 OVERVIEW 85
9.2 IMAGING 88
- 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
  - 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
  - 9.2.1.2 ANALOG MAMMOGRAPHY 90
  - 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
  - 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
  - 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
  - 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
  - 9.2.1.7 OTHERS 90
- 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
  - 9.2.2.1 OPTICAL IMAGING 91
  - 9.2.2.2 BREAST ULTRASOUND 91
  - 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
  - 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
  - 9.2.2.5 BREAST THERMOGRAPHY 92
- 9.2.3 BIOPSY 92
  - 9.2.3.1 SURGICAL BIOPSY 93
  - 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
  - 9.2.3.3 CORE NEEDLE BIOPSY 93
  - 9.2.3.4 IMAGE-GUIDED BIOPSY 93
  - 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
- 9.2.4 GENOMIC TEST 94
  - 9.2.4.1 MOLECULAR TESTING 95
    - 9.2.4.1.1 PD-L1 96
    - 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
    - 9.2.4.1.3 NTRK GENE FUSIONS 96
    - 9.2.4.1.4 PI3KCA GENE MUTATION 96
  - 9.2.4.2 MAMMAPRINT 96
  - 9.2.4.3 ONCOTYPE DX 96
  - 9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98

10 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105

11 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112

12 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119

13 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

13.1 NORTH AMERICA 121
- 13.1.1 U.S. 129
- 13.1.2 CANADA 135
- 13.1.3 MEXICO 141

14 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 147

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 147

15 SWOT ANALYSIS 148

16 COMPANY PROFILE 149

16.1 HOLOGIC, INC. 149
- 16.1.1 COMPANY SNAPSHOT 149
- 16.1.2 REVENUE ANALYSIS 149
- 16.1.3 COMPANY SHARE ANALYSIS 150
- 16.1.4 PRODUCT PORTFOLIO 150
- 16.1.5 RECENT DEVELOPMENTS 151
16.2 SIEMENS HEALTHCARE GMBH 152
- 16.2.1 COMPANY SNAPSHOT 152
- 16.2.2 REVENUE ANALYSIS 153
- 16.2.3 COMPANY SHARE ANALYSIS 153
- 16.2.4 PRODUCT PORTFOLIO 154
- 16.2.5 RECENT DEVELOPMENTS 154
16.3 F. HOFFMANN- LA ROCHE LTD 155
- 16.3.1 COMPANY SNAPSHOT 155
- 16.3.2 REVENUE ANALYSIS 155
- 16.3.3 COMPANY SHARE ANALYSIS 156
- 16.3.4 PRODUCT PORTFOLIO 156
- 16.3.5 RECENT DEVELOPMENTS 157
16.4 KONINKLIJKE PHILIPS N.V. 158
- 16.4.1 COMPANY SNAPSHOT 158
- 16.4.2 REVENUE ANALYSIS 158
- 16.4.3 COMPANY SHARE ANALYSIS 159
- 16.4.4 PRODUCT PORTFOLIO 159
- 16.4.5 RECENT DEVELOPMENTS 160
16.5 ABBOTT 161
- 16.5.1 COMPANY SNAPSHOT 161
- 16.5.2 REVENUE ANALYSIS 161
- 16.5.3 COMPANY SHARE ANALYSIS 162
- 16.5.4 PRODUCT PORTFOLIO 162
- 16.5.5 RECENT DEVELOPMENTS 162
16.6 ABACUS ALS 163
- 16.6.1 COMPANY SNAPSHOT 163
- 16.6.2 PRODUCT PORTFOLIO 163
- 16.6.3 RECENT DEVELOPMENTS 163
16.7 BD 164
- 16.7.1 COMPANY SNAPSHOT 164
- 16.7.2 REVENUE ANALYSIS 164
- 16.7.3 COMPANY SHARE ANALYSIS 165
- 16.7.4 PRODUCT PORTFOLIO 165
- 16.7.5 RECENT DEVELOPMENTS 165
16.8 BIOCEPT, INC. 166
- 16.8.1 COMPANY SNAPSHOT 166
- 16.8.2 REVENUE ANALYSIS 166
- 16.8.3 PRODUCT PORTFOLIO 167
- 16.8.4 RECENT DEVELOPMENTS 167
16.9 BIOMERIEUX 168
- 16.9.1 COMPANY SNAPSHOT 168
- 16.9.2 REVENUE ANALYSIS 168
- 16.9.3 PRODUCT PORTFOLIO 169
- 16.9.4 RECENT DEVELOPMENTS 169
16.10 BIO-RAD LABORATORIES, INC. 170
- 16.10.1 COMPANY SNAPSHOT 170
- 16.10.2 REVENUE ANALYSIS 170
- 16.10.3 PRODUCT PORTFOLIO 171
- 16.10.4 RECENT DEVELOPMENT 171
16.11 CEPHEID 172
- 16.11.1 COMPANY SNAPSHOT 172
- 16.11.2 REVENUE ANALYSIS 172
- 16.11.3 PRODUCT PORTFOLIO 173
- 16.11.4 RECENT DEVELOPMENT 173
16.12 EXACT SCIENCES CORPORATION 174
- 16.12.1 COMPANY SNAPSHOT 174
- 16.12.2 REVENUE ANALYSIS 174
- 16.12.3 COMPANY SHARE ANALYSIS 175
- 16.12.4 PRODUCT PORTFOLIO 175
- 16.12.5 RECENT DEVELOPMENTS 176
16.13 FUJIFILM CORPORATION 177
- 16.13.1 COMPANY SNAPSHOT 177
- 16.13.2 REVENUE ANALYSIS 177
- 16.13.3 PRODUCT PORTFOLIO 178
- 16.13.4 RECENT DEVELOPMENT 178
16.14 GENERAL ELECTRIC 179
- 16.14.1 COMPANY SNAPSHOT 179
- 16.14.2 REVENUE ANALYSIS 179
- 16.14.3 PRODUCT PORTFOLIO 180
- 16.14.4 RECENT DEVELOPMENTS 180
16.15 ILLUMINA, INC. 181
- 16.15.1 COMPANY SNAPSHOT 181
- 16.15.2 REVENUE ANALYSIS 181
- 16.15.3 PRODUCT PORTFOLIO 182
- 16.15.4 RECENT DEVELOPMENTS 182
16.16 MYRIAD GENETICS, INC. 183
- 16.16.1 COMPANY SNAPSHOT 183
- 16.16.2 REVENUE ANALYSIS 183
- 16.16.3 PRODUCT PORTFOLIO 184
- 16.16.4 RECENT DEVELOPMENT 184
16.17 NANOSTRING. 185
- 16.17.1 COMPANY SNAPSHOT 185
- 16.17.2 REVENUE ANALYSIS 185
- 16.17.3 PRODUCT PORTFOLIO 186
- 16.17.4 RECENT DEVELOPMENT 186
- 16.17.5 RECENT DEVELOPMENT 186
16.18 ONCOSTEM. 187
- 16.18.1 COMPANY SNAPSHOT 187
- 16.18.2 PRODUCT PORTFOLIO 187
- 16.18.3 RECENT DEVELOPMENT 187
16.19 PROVISTA DIAGNOSTICS. 188
- 16.19.1 COMPANY SNAPSHOT 188
- 16.19.2 PRODUCT PORTFOLIO 188
- 16.19.3 RECENT DEVELOPMENT 188
16.20 THERMO FISHER SCIENTIFIC INC. 189
- 16.20.1 COMPANY SNAPSHOT 189
- 16.20.2 REVENUE ANALYSIS 189
- 16.20.3 PRODUCT PORTFOLIO 190
- 16.20.4 RECENT DEVELOPMENT 190

17 QUESTIONNAIRE 191

18 RELATED REPORTS 194

LIST OF TABLES

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 42
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 42
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 42
TABLE 4 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 57
TABLE 5 NORTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 6 NORTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 58
TABLE 7 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 59
TABLE 8 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 59
TABLE 9 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 61
TABLE 10 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 61
TABLE 11 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 12 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 63
TABLE 13 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 63
TABLE 14 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 15 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 16 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 65
TABLE 17 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 18 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 66
TABLE 19 NORTH AMERICA BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 20 NORTH AMERICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 21 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 72
TABLE 22 NORTH AMERICA INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 23 NORTH AMERICA DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 24 NORTH AMERICA INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 25 NORTH AMERICA METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 26 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 79
TABLE 27 NORTH AMERICA HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 28 NORTH AMERICA DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 29 NORTH AMERICA CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 30 NORTH AMERICA RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 31 NORTH AMERICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 32 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 87
TABLE 33 NORTH AMERICA DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 34 NORTH AMERICA RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 35 NORTH AMERICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 36 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
TABLE 37 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 38 NORTH AMERICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 39 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 40 NORTH AMERICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 96
TABLE 41 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 42 NORTH AMERICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 96
TABLE 43 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 44 NORTH AMERICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 97
TABLE 45 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 46 NORTH AMERICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 97
TABLE 47 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 48 NORTH AMERICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 98
TABLE 49 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
TABLE 50 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 98
TABLE 51 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 98
TABLE 52 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 53 U.S. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 54 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 55 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 100
TABLE 56 U.S. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 100
TABLE 57 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 58 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 101
TABLE 59 U.S. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 101
TABLE 60 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 101
TABLE 61 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 101
TABLE 62 U.S. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 102
TABLE 63 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 64 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 102
TABLE 65 U.S. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 102
TABLE 66 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 67 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 103
TABLE 68 U.S. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 103
TABLE 69 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
TABLE 70 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 71 U.S. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 104
TABLE 72 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 73 CANADA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 74 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 75 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 106
TABLE 76 CANADA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 106
TABLE 77 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
TABLE 78 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 107
TABLE 79 CANADA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 107
TABLE 80 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
TABLE 81 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 107
TABLE 82 CANADA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 108
TABLE 83 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 84 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 108
TABLE 85 CANADA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 108
TABLE 86 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 87 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
TABLE 88 CANADA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
TABLE 89 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
TABLE 90 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 91 CANADA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 110
TABLE 92 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 93 MEXICO IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 94 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 95 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 112
TABLE 96 MEXICO IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 112
TABLE 97 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
TABLE 98 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 113
TABLE 99 MEXICO NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 113
TABLE 100 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
TABLE 101 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 113
TABLE 102 MEXICO BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 114
TABLE 103 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 104 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 114
TABLE 105 MEXICO GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 114
TABLE 106 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 107 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
TABLE 108 MEXICO MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
TABLE 109 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
TABLE 110 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 111 MEXICO BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 116

LIST OF FIGURES

FIGURE 1 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 31
FIGURE 8 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 33
FIGURE 9 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 37
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 38
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET 46
FIGURE 14 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 54
FIGURE 15 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 55
FIGURE 16 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 55
FIGURE 17 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 56
FIGURE 18 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 69
FIGURE 19 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 70
FIGURE 20 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 70
FIGURE 21 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 71
FIGURE 22 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 76
FIGURE 23 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 77
FIGURE 24 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 77
FIGURE 25 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 78
FIGURE 26 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 84
FIGURE 27 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 85
FIGURE 28 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 85
FIGURE 29 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 86
FIGURE 30 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 91
FIGURE 31 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 92
FIGURE 32 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 92
FIGURE 33 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 93
FIGURE 34 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 93
FIGURE 35 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 116